Dynamics of Epstein-Barr virus on post-transplant lymphoproliferative disorders after antithymocyte globulin-conditioned allogeneic hematopoietic cell transplant.

Julian LindsayJad OthmanMichelle K YongDavid RitchieLynette CheeKimHeng TayShio Yen TioIan KerridgeKeith FayWilliam StevensonChris ArthurSharon C-A ChenDavid C M KongMatthew GreenwoodMirta Maravilla RosasCatherine LiuMonica A Slavin

Published in: Transplant infectious disease : an official journal of the Transplantation Society (2021)

EBV-DNAemia >10 000 IU/ml was the strongest predictor of the development of EBV-PTLD, and progression to this level was rapid in ATG-conditioned HCT recipients. This information may guide EBV-PTLD management strategies in these high-risk patients.

Keyphrases

epstein barr virus
diffuse large b cell lymphoma
end stage renal disease
bone marrow
chronic kidney disease
newly diagnosed
stem cell transplantation
peritoneal dialysis
single cell
cell therapy
healthcare
stem cells